Affinia secures $110M to move gene therapies to clinic

By The Science Advisory Board staff writers

May 3, 2021 -- Affinia Therapeutics has closed $110 million in financing to further develop its proprietary gene therapy platform, to advance its programs to the clinic, and for general corporate purposes.

The company is focused on developing gene therapies for individuals affected by devastating rare and nonrare diseases. Founded in 2019, the company's science is based on work done by Luk Vandenberghe, PhD, associate professor at Massachusetts Eye and Ear and Harvard Medical School and a co-inventor of adeno-associated virus vector 9 (AAV9).

At its facility in Waltham, MA, Affinia is working on advancing its process and analytical development capacities, as well as manufacturing pilot plant capabilities to support its clinical programs.

The series B financing was co-led by EcoR1 Capital and Farallon Capital Management.

Neurogene nabs $115M in series B financing
Neurogene has completed $115 million in series B financing, which will be used to advance various aspects of the company's gene therapy programs...
Nuvation Bio goes public through merger
Nuvation Bio is going public through a merger with Panacea Acquisition, a special purpose acquisition company sponsored by EcoR1 Capital.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter